Publication:
ATRACTIB: A phase II trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)

Simple item page
dc.conference.dateMAY 03-05, 2022
dc.conference.titleEuropean-Society-for-Medical-Oncology (ESMO) Breast Cancer Congress
dc.contributor.authorCortes Salgado, A.
dc.contributor.authorPerez Garcia, J. M.
dc.contributor.authorCortez Castedo, S. P.
dc.contributor.authorGion Cortes, M.
dc.contributor.authorMorales Murillo, S.
dc.contributor.authorBlancas Lopez-Barajas, I.
dc.contributor.authorBlanch, S.
dc.contributor.authorCalvo Plaza, I.
dc.contributor.authorDiaz Fernandez, N.
dc.contributor.authorMarme, F.
dc.contributor.authorMartinez Bueno, A.
dc.contributor.authorTaberner Bonastre, M. T.
dc.contributor.authorDe laurentiis, M.
dc.contributor.authorRuiz Borrego, M.
dc.contributor.authorSchmid, P.
dc.contributor.authorGuarneri, V.
dc.contributor.authorGligorov, J.
dc.contributor.authorSampayo-Cordero, M.
dc.contributor.authorLlombart Cussac, A.
dc.contributor.authorCortes, J.
dc.contributor.authoraffiliation[Cortes Salgado, A.] Hosp Univ Ramon y Cajal, Oncol Med, Madrid, Spain
dc.contributor.authoraffiliation[Perez Garcia, J. M.] Int Breast Canc Ctr IBCC, Dept Med Oncol, Quiron Grp, Barcelona, Spain
dc.contributor.authoraffiliation[Cortez Castedo, S. P.] Complejo Hosp Ruber Juan Bravo, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Gion Cortes, M.] Hosp Univ Ramon y Cajal, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Morales Murillo, S.] Hosp Arnau de Vilanova Lleida, Dept Med Oncol, Alpicat, Spain
dc.contributor.authoraffiliation[Blancas Lopez-Barajas, I.] Hosp Clin San Cecilio, Dept Oncol, Granada, Spain
dc.contributor.authoraffiliation[Blanch, S.] IVO Fdn Inst Valenciano Oncol, Dept Med Oncol, Valencia, Spain
dc.contributor.authoraffiliation[Calvo Plaza, I.] MD Anderson Canc Ctr, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Diaz Fernandez, N.] Hosp Gen Univ Alicante, Dept Med Oncol, Alicante, Spain
dc.contributor.authoraffiliation[Marme, F.] UMM Univ Klinikum Mannheim, Gynecol Oncol Dept, Med Fak, Mannheim, Germany
dc.contributor.authoraffiliation[Martinez Bueno, A.] 11 Hosp Quiron Deixeus, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Taberner Bonastre, M. T.] 12 La Ribera de Alzira Univ Hosp, Dept Med Oncol, Valencia, Spain
dc.contributor.authoraffiliation[De laurentiis, M.] Ist Nazl Tumori IRCCS Fdn Pascale, Dept Breast & Thorac Oncol, Naples, Italy
dc.contributor.authoraffiliation[Ruiz Borrego, M.] Hosp Univ Virgen del Rocio, Dept Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Schmid, P.] Queen Mary Univ London, Ctr Expt Canc Med, Barts Canc Inst, London, England
dc.contributor.authoraffiliation[Guarneri, V.] Univ Padua, Dept Surg, Oncol & Gastroenterol Dept, Padua, Italy
dc.contributor.authoraffiliation[Gligorov, J.] Sorbonne Univ, Hop Tenon, Inst Univ Cancerol AP HP, Oncol Med, Paris, France
dc.contributor.authoraffiliation[Sampayo-Cordero, M.] Med Scientia Innovat Res MEDSIR, Dept Med, Barcelona, Spain
dc.contributor.authoraffiliation[Llombart Cussac, A.] Hosp Arnau Vilanova, Dept Med Oncol, Valencia, Spain
dc.contributor.authoraffiliation[Cortes, J.] Int Breast Canc Ctr IBCC, Dept Oncol, Quiron Grp, Barcelona, Spain
dc.contributor.authoraffiliation[Cortes, J.] Med Scientia Innovat Res MEDSIR, Barcelona, Spain
dc.date.accessioned2023-05-03T14:40:25Z
dc.date.available2023-05-03T14:40:25Z
dc.date.issued2022-05-05
dc.identifier.doi10.1016/j.annonc.2022.03.224
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753422006032/pdf
dc.identifier.urihttp://hdl.handle.net/10668/21907
dc.identifier.wosID792494100208
dc.issue.number3
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationHospital Universitario San Cecilio
dc.organizationHospital Universitario San Cecilio
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationHospital Universitario Virgen del Rocío
dc.page.numberS221-S221
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleATRACTIB: A phase II trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number33
dc.wostypeMeeting Abstract
dspace.entity.typePublication

Files

Collections

SAS - Hospital Universitario San Cecilio
SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía